Physician profile
Ralph Paul Diaz
NPI 1083682629
$1,840.56
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $1,126.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $643.70 | 2019-2020 | |
| Glaxosmithkline, LLC. | $291.53 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $160.49 | 2019-2020 | |
| Optinose US, INC. | $151.69 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.47 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.76 | 2019-2020 | |
| Shire North American Group INC | $70.60 | 2019 | |
| Novartis Pharmaceuticals Corporation | $69.28 | 2019-2020 | |
| Genzyme Corporation | $62.34 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $53.89 | 2019 | |
| Csl Behring | $42.32 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $34.31 | 2019-2020 | |
| Kaleo, INC. | $30.31 | 2019-2020 | |
| Greer Laboratories, INC. | $22.80 | 2019 | |
| Mylan Specialty L.P. | $21.10 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $15.97 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.